POSSIBILITIES OF A COMBINATION OF DOCETAXEL WITH ANDROGEN DEPRIVATION IN INITIAL THERAPY OF HORMONESENSITIVE PROSTATE CANCER

Androgen deprivation therapy (ADT) is used in the treatment of prostate cancer metastatic cancer (PC) since the first description of its hormone dependence in 1941. After receiving the results of a TAX 327 study in 2004, the drug from the taxanes - docetaxel became the main cytostatic agent in the treatment of the castration resistant prostate cancer (CRPC). In a recently publishedstudy CHAARTED it was shown for the first time that the combination of ADT with docetaxel in men with hormone-sensitive metastatic prostate cancer (HSMPC) showed the advantage in the total survival rate by 13.6 months compared to the independent ADT. Similar results were obtained in the STAMPEDE study of men with local-distrubuted and metastatic PC with initial long ADT. A combination of six docetaxel courses with ADT in men starting long-term ADT demonstrated the same advantage by the survival rate parameter compared to the standard ADT by 10 months. Based on the reliability of the treatment results obtained by a new combination of a cytostatic and hormonal product, docetaxel in addition to ADT should be regarded as the basic initial therapy for men with the first identified hormone-sensitive PC, as reflected in the practical recommendations on the treatment of malignant tumours (RUSSCO) 2016 and the recommendations of the European Association of Urologists, 2017.